Sung-jin Hong
Yonsei University · 医学
研究室紹介
Professor Sung-jin Hong's research lab specializes in interventional cardiology and preventive cardiology, with a primary focus on optimizing antiplatelet and lipid-lowering therapies in patients with acute coronary syndrome and atherosclerotic cardiovascular disease. The lab investigates strategies for shortening dual antiplatelet therapy duration after drug-eluting stent implantation, evaluates the efficacy and safety of high-intensity versus treat-to-target statin therapy, and explores novel approaches to improving stent technology and vascular function. Their work is grounded in large-scale, multicenter clinical trials that aim to enhance patient outcomes while minimizing bleeding and adverse effects.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15clinicaltrials.gov Identifier: NCT01308281.
BACKGROUND: Stopping aspirin within 1 month after implantation of a drug-eluting stent for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome. The aim of this study was to investigate whether ticagrelor monotherapy after <1 month of dual antiplatelet therapy (DAPT) is noninferior to 12 months of ticagrelor-based DAPT for adverse cardiovascular and bleeding events in patients with acute coronary syndrome. METHODS: In this randomized, open-label,
Importance: In patients with coronary artery disease, some guidelines recommend initial statin treatment with high-intensity statins to achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). An alternative approach is to begin with moderate-intensity statins and titrate to a specific LDL-C goal. These alternatives have not been compared head-to-head in a clinical trial involving patients with known coronary artery disease. Objective: To assess whether a treat-to-target
BACKGROUND: Modulation of intracellular free calcium is a critical determinant of vasomotor tone. The authors investigated the effects of three benzodiazepines on alpha-adrenergic-induced oscillations in intracellular free calcium in individual pulmonary artery smooth muscle cells. METHODS: Pulmonary artery smooth muscle cells were cultured from explants of canine intrapulmonary artery. Fura-2-loaded pulmonary artery smooth muscle cells were continuously superfused with phenylephrine (10 microM)
The need for further advances in drug-eluting stents or fully bioresorbable coronary scaffolds still exists to improve patient survival or clinical outcomes. The use for different actions or of combinations of drugs with several actions can be potential. Technological refinement and progress in manufacturing to improve mechanical integrity are needed, particularly for fully bioresorbable scaffolds. For antiplatelet therapy after stenting, clinical bleeding reduction strategies, such as a shorten